These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Murray ME; Lowe VJ; Graff-Radford NR; Liesinger AM; Cannon A; Przybelski SA; Rawal B; Parisi JE; Petersen RC; Kantarci K; Ross OA; Duara R; Knopman DS; Jack CR; Dickson DW Brain; 2015 May; 138(Pt 5):1370-81. PubMed ID: 25805643 [TBL] [Abstract][Full Text] [Related]
10. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Driscoll I; Troncoso JC; Rudow G; Sojkova J; Pletnikova O; Zhou Y; Kraut MA; Ferrucci L; Mathis CA; Klunk WE; O'Brien RJ; Davatzikos C; Wong DF; Resnick SM Acta Neuropathol; 2012 Dec; 124(6):823-31. PubMed ID: 22864813 [TBL] [Abstract][Full Text] [Related]
11. Different aspects of Alzheimer's disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia. Thal DR; Ronisz A; Tousseyn T; Rijal Upadhaya A; Balakrishnan K; Vandenberghe R; Vandenbulcke M; von Arnim CAF; Otto M; Beach TG; Lilja J; Heurling K; Chakrabarty A; Ismail A; Buckley C; Smith APL; Kumar S; Farrar G; Walter J Acta Neuropathol Commun; 2019 Nov; 7(1):178. PubMed ID: 31727169 [TBL] [Abstract][Full Text] [Related]
12. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease. Okamura N; Yanai K IDrugs; 2010 Dec; 13(12):890-9. PubMed ID: 21154149 [TBL] [Abstract][Full Text] [Related]
14. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology. Thal DR; Beach TG; Zanette M; Heurling K; Chakrabarty A; Ismail A; Smith AP; Buckley C Alzheimers Dement; 2015 Aug; 11(8):975-85. PubMed ID: 26141264 [TBL] [Abstract][Full Text] [Related]
15. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA; Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397 [TBL] [Abstract][Full Text] [Related]
16. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection. Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679 [TBL] [Abstract][Full Text] [Related]
17. Association of TDP-43 Pathology with Global and Regional 18F-Florbetapir PET Signal in the Alzheimer's Disease Spectrum. Teipel SJ; Temp AGM; Levin F; Dyrba M; Grothe MJ; J Alzheimers Dis; 2021; 79(2):663-670. PubMed ID: 33337372 [TBL] [Abstract][Full Text] [Related]
18. [Amyloid-plaque imaging of the brain using PET]. Ossenkoppele R; Tolboom N; Pijnenburg YA; Lammertsma AA; Scheltens P; van Berckel BN Ned Tijdschr Geneeskd; 2011; 155():A2981. PubMed ID: 21586182 [TBL] [Abstract][Full Text] [Related]